

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Neuroblastoma Cancer in Children](#)

[Brain & Spinal Cord Cancer Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Your child's care team will let you know if your child may be a candidate for any clinical trials. Our clinical research team is highly experienced in selecting the children who are most likely to benefit from a particular investigational therapy. We can guide you through the process of choosing the most appropriate clinical trial to meet your child's needs. All aspects of a clinical trial are explained to you thoroughly, and your decision to enroll your child is entirely voluntary.

## What kinds of therapies are being studied?

One of our approaches has been to take advantage of new drugs already in clinical trials for adults. Some of these drugs can enhance the effectiveness of chemotherapy without adding side effects, especially in people with disease that has become resistant to standard treatment. Other therapies are designed to block the ability of neuroblastoma cells to spread. You can find studies of such treatments as antibodies, cancer vaccines, and other immunotherapies. These studies often offer treatment options for people with neuroblastoma that has continued to grow or that came back despite prior therapies.

## Translational Research for Neuroblastoma

In addition to our clinical researchers, MSK Kids has laboratory investigators who are exploring how neuroblastoma develops, spreads, and resists treatment. We work with clinical researchers to translate the findings of those studies into new options for young patients. The findings of clinical trials can inform new avenues of study.

Search by keywords:

and/or

Trial phase:

Search

### [A Phase 1 Study of Avutometinib, a Dual Inhibitor of MEK and RAF, for Children and Young Adults With Advanced Solid Tumors](#)

Diseases: [Brain Tumors, Primary](#), [Histiocytosis](#), [Neuroblastoma](#), [Pediatric Brain Tumors: Brain Cancer](#), [Sarcomas](#), [Solid Tumors](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Sameer Farouk Sait](#)

---

### [A Phase 1/2 Study of Afamitresgene Autoleucel SPEAR T Cell Therapy in Children and Young Adults With Solid Tumors](#)

Diseases: [Neuroblastoma](#), [Primary Bone: Osteosarcoma](#), [Sarcomas: Osteosarcoma](#), [Sarcomas: Soft Tissue Sarcoma](#)

Locations: [New York City](#), [Commack Nonna's Garden Foundation Center](#), [Basking Ridge](#), [Westchester](#), [Monmouth](#)

[Who Can Join](#)

 [Fiorella Iglesias Cardenas](#)

---

### [A Phase 2 Study of a Vaccine in Combination With Beta-glucan for People With Neuroblastoma With a High Chance of Coming Back](#)

Diseases: [Neuroblastoma](#)

Locations: [New York City](#), [Commack Nonna's Garden Foundation Center](#), [Basking Ridge](#), [Westchester](#), [Monmouth](#)

[Who Can Join](#)

 [Brian H. Kushner](#)

---

### [A Phase I Study of CLR 131 in Children, Adolescents, and Young Adults with Recurrent or Persistent Solid Tumors, Lymphoma, and Brain Tumors](#)

Diseases: [Lymphoma](#), [Lymphoma: Hodgkin's Disease](#), [Neuroblastoma](#), [Pediatric Brain Tumors: Brain Cancer](#), [Sarcomas](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Julia Glade Bender](#)

---

### [A Phase I Study of Idasanutlin Alone or with Chemotherapy in Pediatric and Young Adult Patients with Recurrent or Persistent Solid Tumors](#)

Diseases: [Leukemia: Acute Lymphoblastic Leukemia](#), [Leukemia: Acute Myelocytic](#)

[Leukemia](#), [Leukemia: Acute Myelogenous Leukemia](#), [Neuroblastoma](#), [Solid Tumors](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Tanya M. Trippett](#)

---

### [A Phase I/II Study of Repotrectinib in Children and Young Adults with Advanced or Metastatic Cancers Containing ALK, ROS1, or NTRK1-3 Alterations](#)

Diseases: [Lymphoma: Non-Hodgkin's Lymphoma](#), [Neuroblastoma](#), [Pediatric Brain Tumors: Brain Cancer](#), [Pediatric Brain Tumors: CNS Cancer](#), [Solid Tumors](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Sameer Farouk Sait](#)

---

### [A Phase I/IIA Study of <sup>64</sup>Cu-SARTATE and <sup>67</sup>Cu-SARTATE for Imaging and Treating Children and Young Adults with High-Risk Neuroblastoma](#)

Diseases: [Neuroblastoma](#)

Locations: [New York City](#), [Westchester](#)

[Who Can Join](#)

 [Neeta Pandit-Taskar](#)

---

### [A Phase II Study Assessing a Vaccine in Combination with Beta-glucan and GM-CSF in People with Neuroblastoma](#)

Diseases: [Neuroblastoma](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Brian H. Kushner](#)

---

### [A Phase II Study of <sup>131</sup>I-MIBG Alone or with Vorinostat in People with High-Risk Neuroblastoma](#)

Diseases: [Neuroblastoma](#)

Locations: [New York City](#), [Commack Nonna's Garden Foundation Center](#), [Basking Ridge](#), [Westchester](#), [Monmouth](#)

[Who Can Join](#)

 [Ellen M. Basu](#)

---

### [A Pilot Phase II Study of Targeted Radiotherapy with <sup>131</sup>I-MIBG and Arsenic](#)

## [Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors](#)

Diseases: [Neuroblastoma](#)

Locations: [New York City](#)

[Who Can Join](#)

 [Ellen M. Basu](#)

[Load More](#)

### ▾ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

800-525-2225



### ▾ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

### ▾ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

### ▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center